Skip to main content
Equibles
GLSI logo

GLSI · Greenwich LifeSciences, Inc.

Track GLSI — free

Use GLSI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GLSI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.28 -0.81 (-5.03%) At close · Nov 12
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has prepared its financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.”
View the 10-Q filed Aug 11, 2026
Market Cap
$224.28M
Shares
14.68M
Volume · Nov 12 207.01K Avg daily vol (3M) 129.33K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$15.28 Open$15.80 Day$14.40–16.08 52W close$7.85–33.57 Avg vol 30d137K Short int1.6M · 10.8% of shares · 12.5d Short vol43% DataSep 2020–Nov 2026 Filing10-Q · Aug 11

Latest documents

2026
Oct 26
Annual report to holders ARS
Annual report to holders

Greenwich LifeSciences is enrolling patients in Phase III Flamingo-01, evaluating GLSI-100 to prevent breast cancer recurrence, and expanding into Europe with plans for up to 150 sites globally. It needs significant additional financing for operations and product development.

Read from the first part of this long document
Oct 26
Proxy statement DEF 14A
Proxy statement

Greenwich LifeSciences, Inc. will ask stockholders on December 18, 2026 to elect five (5) directors, ratify MaloneBailey LLP for the fiscal year ending December 31, 2026, approve advisory executive compensation, and choose future advisory-vote frequency.

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$22.47M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$8.88M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+9.4%
Year over year · more shares
Price change (1Y)
+90.0%
Trailing year
Short interest
10.8%
Latest settlement · 12.5 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 18.7 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −27%
below
Price vs 50-day avg −8%
below
RSI (14) 45
neutral
MACD trend Negative
52-week position 29%
mid-range
Momentum
relative strength
Very Weak
1-month return 0%
trailing
6-month return −45%
trailing
YTD return −27%
this year
Relative strength −46%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $17 › 200d $21 — 200d above 50d
Institutional flow Distributing
34 of 59 funds reported for Sep 30 · net -22.9K sh shares · +3 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.75% of shares out · ▲ +1.7% MoM · 12.5 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
59 holders — mid 3-yr range
Squeeze score 73
high risk · 0–100
Fundamentals
Fair
EPS growth −7%
Y/Y
Balance sheet $6.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 106%
annualized · 1-yr
Max drawdown −62%
past year
ATR 9.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−27% Bearish
Price vs 50-day avg
−8% Bearish
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
29% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $17 › 200d $21 — 200d above 50d
Institutional flow Distributing
34 of 59 funds reported for Sep 30 · net -22.9K sh shares · +3 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.75% of shares out · ▲ +1.7% MoM · 12.5 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
59 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $8 Now $15 · 29% Range high $34
vs 200-day avg -27% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GLSI
Greenwich LifeSciences, Inc.
this stock
$224.28M -27.3% — — 10.8%
VRTX
Vertex Pharmaceuticals Inc
 $137.57B +19.7% +46.2% 34.9 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.40B +23.2% +20.8% 21.0 2.1%
MRNA
Moderna, Inc.
 $93.61B +684.5% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.55B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
58
% held
11.4%
Reported
34 of 59
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
80
View
Short & Settlement
Short Interest Rising
Shares short
1.6M
Days to cover
12.5d
Change
+25.8K sh
View
Short Volume
Short vol %
43%
As of
Nov 12, 2026
Short Total
View
Fails to Deliver
FTD shares
31.7K
Value
$490.9K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
33.2%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-19.4M
EPS diluted
$-1.43
View
Buybacks
Authorized
shares 519.8K
View
Filings
SEC Filings
Latest
DEF 14A
Filed
Oct 26, 2026
This year
7

Greenwich LifeSciences, Inc. will ask stockholders on December 18, 2026 to elect five (5) directors, ratify MaloneBailey LLP for the fiscal year ending December 31, 2026, approve advisory executive compensation, and choose future advisory-vote frequency.

View
Exempt Offerings
Offering
$2.5M
Filed
Jun 18, 2024
View
Earnings & Events
Webcasts
Last webcast
Dec 3, 2025
View

Performance

5D 20D 120D MTD YTD
GLSI +4.3% -0.3% -44.7% -12.2% -27.3%
SPY +3.3% -1.9% +1.5% +0.2% +11.0%
vs SPY +1.0% +1.6% -46.3% -12.4% -38.3%

Capital returns

Buyback program · as of Dec 31, 2023
Authorized
shares 519,828
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1799788 CUSIP 396879108 13F (30d) 56 filings 30 filers Visit website Investor relations